Related Experiment Video

Updated: Jul 13, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Thyroid cancer molecular signaling pathways and use of targeted therapy

Priya Kundra1, Kenneth D Burman

  • 1Endocrine Sections, Washington Hospital Center, Georgetown University Medical Center, 110 Irving Street, NW, Washington, DC 20010, USA.

Endocrinology and Metabolism Clinics of North America
|August 4, 2007
PubMed

Insights

New targeted therapies are being developed to treat thyroid cancer by focusing on molecular signaling pathways and cancer cell biology. These innovative treatments offer hope for patients with thyroid cancer resistant to conventional therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Thyroid cancer treatment traditionally relies on established therapies.
  • Some thyroid cancers become unresponsive to conventional treatments.
  • Molecular signaling pathways and cancer cell biology are key areas for novel therapeutic development.

Purpose of the Study:

  • To review emerging targeted agents for thyroid cancer.
  • To highlight molecular pathways and cellular mechanisms being targeted.
  • To discuss the potential of these agents for refractory thyroid cancer.

Main Methods:

  • Review of current research on targeted therapies for thyroid cancer.
  • Identification of key molecular pathways and targets (e.g., Ras pathway, growth factor receptors).
  • Categorization of therapeutic approaches including inhibitors and gene therapy.

Main Results:

  • Several targeted agents are under investigation.
  • These agents target specific molecular signaling pathways and cancer cell biology.
  • Promising results are emerging for agents targeting Ras pathway, VEGF/EGF receptors, and others.

Conclusions:

  • Targeted therapies show significant promise for treating thyroid cancer.
  • These approaches offer new hope for patients with treatment-resistant thyroid cancer.
  • Further research and clinical trials are essential to validate these novel treatments.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...